Beyond Air, Inc. (XAIR )

Currency in USD Disclaimer
$0.21 -$0.02 (-9.92%)
Open 04/24/2025
$0.21
$0.23
$0.21
$1.49

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol XAIR
  • Company Beyond Air, Inc.
  • Price $0.21
  • Changes Percentage -9.92
  • Change -0.0228
  • Day Low $0.21
  • Day High $0.23
  • Year High $1.49
  • Year Low $0.21
  • Market Cap $18,282,508
  • Price Avg 50 EMA (D) $0.28
  • Price Avg 200 EMA (D) $0.41
  • Exchange NASDAQ
  • Volume 2,705,911
  • Average Volume 1,729,708
  • Open $0.21
  • Previous Close $0.23
  • EPS -1
  • PE -0.21
  • Earnings Announcement 2025-06-23 10:59:00
  • Shares Outstanding $88,278,650

Company brief: BEYOND AIR, INC. (XAIR )

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

XAIR Corporation News

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

April 21, 2025 at 8:05 pm ET

globenewswire.com -- The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder...

Income Statement